NFKB1 and primary cutaneous T-cell non-Hodgkin lymphoma: Having in mind the published scientific data on the therapeutic approaches for CTCL and the gaps in this research area, we set ourselves the goal to evaluate in detail the in vitro pharmacological potential of basically new therapeutic modalities for targeted inhibition of signal transduction pathways involved in the carcinogenesis of CTCL such as TWIST1, PKB/Akt and NF-κB.